The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Insights into the influence of cardiovascular toxicity risk on treatment selection in CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses how cardiovascular (CV) toxicity risks influence treatment selection for patients with chronic lymphocytic leukemia (CLL). CV toxicities are a class side effect of BTK inhibitors (BTKis), but clinicians can tailor the specific BTKi to each patient based on the individual risk profile of each agent. Dr Eichhorst highlights the importance of communication in managing patients’ expectations for treatment and for hematologists and cardiologists to collaborate to manage CV toxicities. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
